When will the breast cancer vaccine be available? They will closely monitor the participants for side effects and immune response. The trial will include a larger number of participants, who will be in good health, if the dosage proves to be safe and effective. The study has funding from the Department of Defense, and the team expects to complete it in September 2022.
What is the survival rate of triple-negative breast cancer?
|SEER Stage||5-year Relative Survival Rate|
|All stages combined||77%|
Can triple-negative breast cancer come back? Recurrence Rates
According to a 2019 study, around 40% of people who have stage 1 to stage 3 triple-negative breast cancer will have a recurrence following standard treatment, while around 60% will have long-term disease-free survival.
What is the breast cancer vaccine called? A vaccine called NeuVax is furthest along in the research. It treats HER2-positive breast cancer, a type that contains a protein called human epidermal growth factor receptor 2 (HER2). Up to 30% of breast cancers make HER2 in large amounts, which helps the cancer cells grow.